Abstract
A retrospective analysis was carried out to determine the neutropenia-associated factors that require the use of granulocytes-colony stimulating factor (G-CSF) in paclitaxel (PTX) plus carboplatin (CBDCA) combination chemotherapy for the treatment of advanced lung cancer.
Forty-five patients (110 courses) with advanced lung cancer who received PTX plus CBDCA combination chemotherapy were the subjects of the present study.They had no previous treatment history.A logistic regression analysis was performed to determine patient backgrounds and therapeutic regimens that affect the incidence of neutropenia requiring G-CSF.The data showed that the risk factors involving the prolongation of G-CSF use were the monthly dosage regimen[odds ratio : 3.343(95% confidence interval : 1.292-8.648)],dose of PTX≥140 mg/m2 [7.529 (1.669-33.961)] and multiple(>2)courses of the chemotherapy[3.178 (1.228-8.222)].However,the duration of G-CSF use was not influenced by gender,age,performance status,serum albumin or radiation therapy.
These findings suggest that pharmacists should carefully monitor the serological data on myeloid function in patients undergoing PTX plus CBDCA combination chemotherapy for advanced lung cancer,particularly in those with risk factors for prolongation of G-CSF use.
